Carregant...

Inhibition of the human proteasome by imidazoline scaffolds

The proteasome has emerged as the primary target for the treatment of multiple myeloma. Unfortunately, nearly all patients develop resistance to competitive-type proteasome inhibitors, such as bortezomib. Herein, we describe the optimization of non-competitive proteasome inhibitors to yield derivati...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Azevedo, Lauren M., Lansdell, Theresa A., Ludwig, Jacob R., Mosey, Robert A., Woloch, Daljinder K., Cogan, Dillon P., Patten, Gregory P., Kuszpit, Michael R., Fisk, Jason S., Tepe, Jetze J.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3844044/
https://ncbi.nlm.nih.gov/pubmed/23789888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/jm400235r
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!